Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-395 PK Study in Healthy Male Volunteers
NCT02627027Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone + metformin in type 2 diabetes mellitus (T2DM), sponsored by Chong Kun Dang Holdings. Started Aug 2015; status: completed.
02
Drugs
lobeglitazone + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02627027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627027.